Misonix BoneScalpel™ Subject of New Clinical Paper Focused on Spine Surgery

 Misonix BoneScalpel™ Subject of New Clinical Paper Focused on Spine Surgery

PR Newswire

FARMINGDALE, N.Y., March 26, 2013

FARMINGDALE, N.Y., March 26, 2013 /PRNewswire/ --Misonix, Inc. (NasdaqGM:
MSON), an international surgical device company that designs, manufactures and
markets innovative therapeutic ultrasonic products for spine surgery,
skull-based surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, announces a new clinical
paper accepted for publication by "Neurosurgery," the journal of the Congress
of Neurological Surgeons, a well-respected, peer-reviewed journal circulated
to neurosurgeons throughout the world. The paper is entitled "Ultrasonic Bone
Scalpel for Osteoplastic Laminoplasty in the Resection of Intradural Spinal
Pathology: Case Series and Technical Note," and is authored by Parker,
Kretzer, Recinos, et al., and is based on surgeries performed at the Johns
Hopkins Hospital, Baltimore, Maryland. Laminoplasty, like laminectomy, is a
procedure aimed at relieving pressure on the spinal cord, caused by a variety
of conditions. Laminoplasty is often preferred versus laminectomy as it may
offer certain longer term advantages, such as decreasing the incidence of
progressive kyphosis (curvature) of the spine and facilitating post-operative
osteo-integration, which is the forming of functional and structural integrity
between native bone and artificial implants.

The objective going into the 40-patient study was to determine the safety and
technical feasibility of using the BoneScalpel for osteoplastic laminoplasty
based on the ability of the device to precisely cut bone while preserving the
underlying soft tissues and the potential positive impact on post- surgical
osteo-integration. Successful laminoplasty was carried out in all 40 cases
with no incidence of spinal instability during the follow-up period. A
primary soft tissue complication was reduced by more than 40% versus
previously reported institutional rates.

The Misonix BoneScalpel which was used to perform the study, is a novel
ultrasonic osteotome (bone cutting device) used for safe, tissue-selective
bone dissection that encourages en-bloc bone removal and refined osteotomies
while sparing elastic soft tissue structures. Most users report that the
surgical field is relatively bloodless and clean. Loss of viable bone is
minimal and controllable. The BoneScalpel has been used extensively for bone
removal in the cervical, thoracic and lumbar spine, including deformity
surgery.

"In clinicals performed around the world, the BoneScalpel has been shown to
result in less bleeding, greater visibility, less bone loss and greater
patient safety. We are gratified to continue to receive reports such as this
one, which demonstrate impressive clinical results with the Misonix
BoneScalpel when used in delicate spine surgery," said Michael A. McManus,
Jr., President and Chief Executive Officer of Misonix. "It is our privilege to
provide state-of-the-art ultrasonic surgical technology to prestigious
institutions, such as Johns Hopkins, throughout the world."

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at
www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.

                   Investor Relations Contacts:
Misonix Contact:  Lytham Partners, LLC
Richard Zaremba   Robert Blum, Joe Dorame, Joe Diaz
631-694-9555      602-889-9700
invest@misonix.com mson@lythampartners.com

SOURCE Misonix, Inc.

Website: http://www.misonix.com